PLoS ONE, 2021 PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada +10 more
doaj +1 more source
Eosinophilic cystitis refractory to steroids successfully treated with benralizumab: A case report
Frontiers in Allergy, 2023 We report a case of a 66-year-old male diagnosed with refractory to oral corticosteroids eosinophilic cystitis (EoC). Hematuria was the first and only sign of the disease that was otherwise asymptomatic, and the only abnormal lab finding he had was ...
George N. Konstantinou +1 more
doaj +1 more source
Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]
, 2019 Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke +4 more
core +1 more source
Frontiers in Medicine, 2022 BackgroundSevere asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of ...
Cristiano Caruso +27 more
doaj +1 more source
Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]
, 2018 According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca +6 more
core +2 more sources
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]
, 2017 Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy +4 more
core +3 more sources
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma [PDF]
, 2013 Peer reviewedPublisher ...
Walsh, Garry Michael
core +2 more sources
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia:Case report [PDF]
, 2021 A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection.
Bethlehem, Carina +4 more
core +1 more source
We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]
, 2018 Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4, +3 more
core +1 more source